Need Help? Contact Us.

Enquire now

Growth

A Unique, Comprehensive and Efficient solution for Growth Disorder Management

There are two main types of growth disorders: excessive growth and growth-hormone deficiency (GHD).

Acromegaly is the most common disorder of excess growth hormone (GH) secretion, caused by hypersecretion of IGF-I. Early detection of acromegaly is key, as the pathological effects of increased GH production are progressive.

GHD occurs when the pituitary gland does not make enough GH. Its cause is mainly unknown; however it may be present at birth or develop later as a result of an injury or medical condition. Slow growth may first be noticed in infancy and continue through childhood. In adults possible causes include tumours involving the pituitary gland or hypothalamus, or brain radiation treatments for cancer.

IDS Growth Disorders assays conform to the consensus statement on the Standardisation and Evaluation of GH and IGF-I assays.1 They are supported by the largest published reference interval study on IGF-I 2 and IGFBP-3 3 levels in adults and children. Our assay-specific cut-offs for GH stimulation and suppression tests are available in key peer-reviewed publications 4-8.

Our Growth Disorders tests porfolio provides a comprehensive, unique and efficient tool to assist in the diagnosis and treatment monitoring of growth hormone disorders:

  • Identify diseases and conditions caused by either a deficiency, or overproduction of GH
  • Monitor the effectiveness of GH treatment through evaluating levels of IGF-I 2
  • Evaluate symptoms of GH abnormalities
  • As a follow-up to other abnormal hormone test results
  • Help understand pituitary gland function
  • Aid in diagnosis of paediatric GH disorders as patients with GHD have sub-normal IGFBP-3 level
  1. Clemmons, D. Clin Chem. 57:4 (2011)
  2. Bidlingmaier, M. et al. JCEM 99:5 (2014)
  3. Friedrich, N. et al. JCEM 99:5 (2014)
  4. Schillbach, K. et al. Eur J Endocrinol. 181 (2019)
  5. Manolopoulou, J. et al. Clin Chem. 58:10 (2012)
  6. Klose, M. et al. JCEM 99:1 (2014)
  7. Wagner, IV. et al. Eur J of 171 (2014)
  8. Deutschbein, T. et al. Eur J Endocrinol. 176:3 (2017)

Growth Products

Filter Products

Type

Portfolio

Panel

Platform

Certification

Assays Certification Platform Clinical Area Portfolio RUO/IVD
Human Growth Hormone (hGH) CE MarkedFDA Cleared i10iSYS Growth Endocrinology IVD
Insulin Like Growth Factor-I (IGF-I) CE MarkedFDA Cleared i10iSYS Growth Endocrinology IVD
Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) CE MarkedFDA Cleared i10iSYS Growth Endocrinology IVD

Filter Products

Portfolio

Certification

Platform

Clinical Area

Ruo/IVD

Unsure? Contact Us.

Enquire now

Need more information? Enquire now.

This site is registered on wpml.org as a development site.